Feed Top Reports Pricing

⌘K

16:12:55·7d

SECFiling

SEC Form DEFA14A filed by Esperion Therapeutics Inc.

ESPR· Esperion Therapeutics Inc.

Health Care

Original source

Companies

ESPR
Esperion Therapeutics Inc.
Health Care

Recent analyst ratings

Nov 25UpdatePiper Sandler$9.00
Dec 18UpdateGoldman$4.00
Dec 17UpdateCantor Fitzgerald$8.00
Jun 20UpdateBofA Securities$2.50
Jan 3UpdateBofA Securities-
Nov 20UpdateJP Morgan-

Related

PR1d
Esperion to Report First Quarter 2026 Financial Results on May 7
SEC1d
SEC Form SCHEDULE 13G filed by Esperion Therapeutics Inc.
SEC7d
SEC Form DEF 14A filed by Esperion Therapeutics Inc.
SEC21d
Esperion Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
PR21d
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
PR21d
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
PR24d
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
PR25d
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022